Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination

Journal of Virology

Volumn 79, Issue 14, 2005, Pages 8960-8968

  Wherry, E John ^a,c   Blattman, Joseph N ^b   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IMMUNE RESPONSE; INFECTION CONTROL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; VACCINATION; VIRUS CULTURE; VIRUS INFECTION; VIRUS LOAD;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; VACCINATION; VIRAL LOAD; VIRAL VACCINES;

LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MURINAE; VACCINIA VIRUS;

EID: 21644453108     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.14.8960-8968.2005     Document Type: Article

References (44)

1. Ahmed, R., and M. B. Oldstone. 1988. Organ-specific selection of viral variants during chronic infection. J. Exp. Med. 167:1719-1724. (Erratum, 168:457.)
2. Ahmed, R., A. Salmi, L. D. Butler, J. M. Chiller, and M. B. Oldstone. 1984. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160:521-540.
3. Allen, T. M., D. H. O'Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, K. J. Kunstman, X. Wang, D. B. Allison, A. L. Hughes, R. C. Desrosiers, J. D. Altman, S. M. Wolinsky, A. Sette, and D. I. Watkins. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386-390.
4. Autran, B., G. Carcelain, B. Combadiere, and P. Debre. 2004. Therapeutic vaccines for chronic infections. Science 305:205-208.
5. Blattman, J. N., J. M. Grayson, E. J. Wherry, S. M. Kaech, K. A. Smith, and R. Ahmed. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9:540-547.
6. Bocher, W. O., B. Dekel, W. Schwerin, M. Geissler, S. Hoffmann, A. Rohwer, F. Arditti, A. Cooper, H. Bernhard, A. Berrebi, S. Rose-John, Y. Shaul, P. R. Galle, H. F. Lohr, and Y. Reisner. 2001. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur. J. Immunol. 31:2071-2079.
7. Brenchley, J. M., N. J. Karandikar, M. R. Betts, D. R. Ambrozak, B. J. Hill, L. E. Crotty, J. P. Casazza, J. Kuruppu, S. A. Migueles, M. Connors, M. Roederer, D. C. Douek, and R. A. Koup. 2003. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101:2711-2720.
8. Chen, L. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4:336-347.
9. Dikici, B., A. G. Kalayci, F. Ozgenc, M. Bosnak, M. Davutoglu, A. Ece, T. Ozkan, T. Ozeke, R. V. Yagci, and K. Haspolat. 2003. Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr. Infect. Dis. J. 22:345-349.
10. Dittmer, U., H. He, R. J. Messer, S. Schimmer, A. R. Olbrich, C. Ohlen, P. D. Greenberg, I. M. Stromnes, M. Iwashiro, S. Sakaguchi, L. H. Evans, K. E. Peterson, G. Yang, and K. J. Hasenkrug. 2004. Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity 20:293-303.
11. Douek, D. C., L. J. Picker, and R. A. Koup. 2003. T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 21:265-304.
12. Fuller, M. J., and A. J. Zajac. 2003. Ablation of CD8 and CD4 T cell responses by high viral loads. J. Immunol. 170:477-486.
13. Grayson, J. M., L. E. Harrington, J. G. Lanier, E. J. Wherry, and R. Ahmed. 2002. Differential sensitivity of naive and memory CD8(+) T cells to apoptosis in vivo. J. Immunol. 169:3760-3770.
14. Harrington, L. E., R. van der Most, J. L. Whitton, and R. Ahmed. 2002. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol. 76:3329-3337.
15. Hel, Z., D. Venzon, M. Poudyal, W. P. Tsai, L. Giuliani, R. Woodward, C. Chougnet, G. Shearer, J. D. Altman, D. Watkins, N. Bischofberger, A. Abimiku, P. Markham, J. Tartaglia, and G. Franchini. 2000. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat. Med. 6:1140-1146.
16. + T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J. Virol. 77:10900-10909.
17. Jamieson, B. D., L. D. Butler, and R. Ahmed. 1987. Effective clearance of a persistent viral infection requires cooperation between virus-specific Lyt2+ T cells and nonspecific bone marrow-derived cells. J. Virol. 61:3930-3937.
18. Jung, M. C., N. Gruner, R. Zachoval, W. Schraut, T. Gerlach, H. Diepolder, C. A. Schirren, M. Page, J. Bailey, E. Birtles, E. Whitehead, J. Trojan, S. Zeuzem, and G. R. Pape. 2002. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 20:3598-3612.
19. Kaech, S. M., S. Hemby, E. Kersh, and R. Ahmed. 2002. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111:837-851.
20. Keadle, T. L., K. A. Laycock, J. L. Morris, D. A. Leib, L. A. Morrison, J. S. Pepose, and P. M. Stuart. 2002. Therapeutic vaccination with vhs(-) herpes simplex virus reduces the severity of recurrent herpetic stromal keratitis in mice. J. Gen. Virol. 83:2361-2365.
21. + T cells. J. Virol. 78:10953-10959.
22. Lindenburg, C. E., I. Stolte, M. W. Langendam, F. Miedema, I. G. Williams, R. Colebunders, J. N. Weber, M. Fisher, and R. A. Coutinho. 2002. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 20:2343-2347.
23. Lu, W., L. C. Arraes, W. T. Ferreira, and J. M. Andrieu. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10:1359-1365.
24. Lu, W., X. Wu, Y. Lu, W. Guo, and J. M. Andrieu. 2003. Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 9:27-32.
25. Matano, T., R. Shibata, C. Siemon, M. Connors, H. C. Lane, and M. A. Martin. 1998. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72:164-169.
26. Migueles, S. A., A. C. Laborico, W. L. Shupert, M. S. Sabbaghian, R. Rabin, C. W. Hallahan, D. Van Baarle, S. Kostense, F. Miedema, M. McLaughlin, L. Ehler, J. Metcalf, S. Liu, and M. Connors. 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3:1061-1068.
27. Naniche, D., and M. B. Oldstone. 2000. Generalized immunosuppression: how viruses undermine the immune response. Cell Mol. Life Sci. 57:1399-1407.
28. Nevens, F., T. Roskams, H. Van Vlierberghe, Y. Horsmans, D. Sprengers, A. Elewaut, V. Desmet, G. Leroux-Roels, E. Quinaux, E. Depla, S. Dincq, C. Vander Stichele, G. Maertens, and F. Hulstaert. 2003. A pilot study of therapeutic vaccination with envelope protein El in 35 patients with chronic hepatitis C Hepatology 38:1289-1296.
29. Oxenius, A., D. A. Price, A. Trkola, C. Edwards, E. Gostick, H. T. Zhang, P. J. Easterbrook, T. Tun, A. Johnson, A. Waters, E. C. Holmes, and R. E. Phillips. 2004. Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies. J. Infect. Dis. 190:713-721.
30. Pancholi, P., D. H. Lee, Q. Liu, C. Tackney, P. Taylor, M. Perkus, L. Andrus, B. Brotman, and A. M. Prince. 2001. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33:448-454.
31. Richards, C. M., R. Case, T. R. Hirst, T. J. Hill, and N. A. Williams. 2003. Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice. J. Virol. 77:6692-6699.
32. Sakaguchi, S. 2004. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531-562.
33. Sevilla, N., S. Kunz, A. Holz, H. Lewicki, D. Homann, H. Yamada, K. P. Campbell, J. C. de La Torre, and M. B. Oldstone. 2000. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. 192:1249-1260.
34. Sevilla, N., D. B. McGavern, C. Teng, S. Kunz, and M. B. Oldstone. 2004. Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. J. Clin. Investig. 113:737-745.
35. Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2:116-126.
36. Slifka, M. K., D. Homann, A. Tishon, R. Pagarigan, and M. B. Oldstone. 2003. Measles virus infection results in suppression of both innate and adaptive immune responses to secondary bacterial infection. J. Clin. Investig. 111:805-810.
37. Suvas, S., U. Kumaraguru, C. D. Pack, S. Lee, and B. T. Rouse. 2003. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J. Exp. Med. 198:889-901.
38. Tryniszewska, E., J. Nacsa, M. G. Lewis, P. Silvera, D. Montefiori, D. Venzon, Z. Hel, R. W. Parks, M. Moniuszko, J. Tartaglia, K. A. Smith, and G. Franchini. 2002. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J. Immunol. 169:5347-5357.
39. Veiga-Fernandes, H., and B. Rocha. 2004. High expression of active CDK6 in the cytoplasm of CD8 memory cells favors rapid division. Nat. Immunol. 5:31-37.
40. von Herrath, M. G., D. P. Berger, D. Homann, T. Tishon, A. Sette, and M. B. Oldstone. 2000. Vaccination to treat persistent viral infection. Virology 268:411-419.
41. Wherry, E. J., and R. Ahmed. 2004. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78:5535-5545.
42. Wherry, E. J., D. L. Barber, S. M. Kaech, J. N. Blattman, and R. Ahmed. 2004. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl. Acad. Sci. USA 101:16004-16009.
43. Wherry, E. J., J. N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77:4911-4927.
44. Wherry, E. J., V. Teichgraber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:225-234.